Peripheral CD4<sup>+</sup>CD8<sup>+</sup> double positive T cells: A potential marker to evaluate renal impairment susceptibility during systemic lupus erythematosus

Kai Chang; Wanlin Na; Chenxia Liu; Hongxuan Xu; Yuan Liu; Yanyan Wang; Zhongyong Jiang

doi:10.7555/JBR.36.20220094

Volume 37 Issue 1

Jan. 2023

Turn off MathJax

Article Contents

Article Navigation > The Journal of Biomedical Research > 2023 > 37(1): 59-68

Kai Chang, Wanlin Na, Chenxia Liu, Hongxuan Xu, Yuan Liu, Yanyan Wang, Zhongyong Jiang. Peripheral CD4+CD8+ double positive T cells: A potential marker to evaluate renal impairment susceptibility during systemic lupus erythematosus[J]. The Journal of Biomedical Research, 2023, 37(1): 59-68. doi: 10.7555/JBR.36.20220094

Citation:

Kai Chang, Wanlin Na, Chenxia Liu, Hongxuan Xu, Yuan Liu, Yanyan Wang, Zhongyong Jiang. Peripheral CD4⁺CD8⁺ double positive T cells: A potential marker to evaluate renal impairment susceptibility during systemic lupus erythematosus[J]. The Journal of Biomedical Research, 2023, 37(1): 59-68. doi: 10.7555/JBR.36.20220094

Citation:

PDF( 4478 KB)

Peripheral CD4⁺CD8⁺ double positive T cells: A potential marker to evaluate renal impairment susceptibility during systemic lupus erythematosus

doi: 10.7555/JBR.36.20220094

1.
Department of Medical Laboratory, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083, China
2.
Institute of Microbiology, Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan 610044, China
3.
Biology Teaching and Research Group, Chengdu Experimental Foreign Languages School, Chengdu, Sichuan 611134, China
4.
Department of Medical Laboratory, Affiliated Cancer Hospital of Chengdu Medical College, Chengdu Seventh People's Hospital, Chengdu, Sichuan 610231, China

More Information

Corresponding author: Yanyan Wang and Zhongyong Jiang, Division of Cellular and Molecular Diagnostics, Department of Medical Laboratory, The General Hospital of Western Theater Command, 270 Rong Du Avenue, Jinniu District, Chengdu, Sichuan 610083, China. E-mails: wangyanyanmail@126.com and jiangzhongyongmail@126.com;
Received: 2022-04-27
Revised: 2022-07-31
Accepted: 2022-08-04

Published: 2022-09-28

Issue Date: 2023-01-28

Abstract

Abstract

Lupus nephritis (LN) has a high incidence in systemic lupus erythematosus (SLE) patients, but there is a lack of sensitive predictive markers. The purpose of the study was to investigate the association between the CD4⁺CD8⁺ double positive T (DPT) lymphocytes and LN. The study included patients with SLE without renal impairment (SLE-NRI), LN, nephritic syndrome (NS), or nephritis. Peripheral blood lymphocyte subsets were analyzed by flow cytometry. Biochemical measurements were performed with peripheral blood in accordance with the recommendations proposed by the National Center for Clinical Laboratories. The proportions of DPT cells in the LN group were significantly higher than that in the SLE-NRI group (t=4.012, P<0.001), NS group (t=3.240, P=0.001), and nephritis group (t=2.57, P=0.011). In the LN group, the risk of renal impairment increased significantly in a DPT cells proportion-dependent manner. The risk of LN was 5.136 times (95% confidence interval, 2.115–12.473) higher in cases with a high proportion of DPT cells than those whose proportion of DPT cells within the normal range. These findings indicated that the proportion of DPT cells could be a potential marker to evaluate LN susceptibility, and the interference of NS and nephritis could be effectively excluded when assessing the risk of renal impairment during SLE with DPT cell proportion.
- CD4⁺CD8⁺ double positive T cells,
- lupus nephritis,
- susceptibility,
- systemic lupus erythematosus

CLC number: R593.242, Document code: A
The authors reported no conflict of interests.

FullText(HTML)

References(26)

References

[1]	Yu F, Haas M, Glassock R, et al. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes[J]. Nat Rev Nephrol, 2017, 13(8): 483–495. doi: 10.1038/nrneph.2017.85
[2]	Delarche A, Lumbroso C, Fournier A, et al. Incidence and outcome of lupus nephritis in French Polynesia[J]. Clin Nephrol, 2018, 89: 41–49. doi: 10.5414/CN109194
[3]	Feng X, Pan W, Liu L, et al. Prognosis for hospitalized patients with systemic lupus erythematosus in China: 5-year update of the Jiangsu cohort[J]. PLoS One, 2016, 11(12): e0168619. doi: 10.1371/journal.pone.0168619
[4]	Wang S, Shen H, Bai B, et al. Increased CD4+CD8+ double-positive T Cell in patients with primary Sjögren's syndrome correlated with disease activity[J]. J Immunol Res, 2021, 6658324. doi: 10.1155/2021/6658324
[5]	Marrero YT, Suárez VM, Abraham CMM, et al. Immunophenotypic characterization of double positive T lymphocytes in Cuban older adults[J]. Exp Gerontol, 2021, 152: 111450. doi: 10.1016/j.exger.2021.111450
[6]	Rahemtullah A, Harris NL, Dorn ME, et al. Beyond the lymphocyte predominant cell: CD4⁺CD8⁺ T-cells in nodular lymphocyte predominant Hodgkin lymphoma[J]. Leuk Lymphoma, 2008, 49(10): 1870–1878. doi: 10.1080/10428190802308728
[7]	Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J]. Arthritis Rheumatol, 2019, 71(9): 1400–1412. doi: 10.1002/art.40930
[8]	Fanouriakis A, Tziolos N, Bertsias G, et al. Update οn the diagnosis and management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2021, 80(1): 14–25. doi: 10.1136/annrheumdis-2020-218272
[9]	Jiang Z, Liu X, Chang K, et al. Allyl isothiocyanate inhibits the proliferation of renal carcinoma cell line GRC-1 by inducing an imbalance between Bcl2 and Bax[J]. Med Sci Monit, 2016, 22: 4283–4288. doi: 10.12659/MSM.897315
[10]	Chang K, Jiang Z, Liu C, et al. The effects of CYP2C19 genotype on the susceptibility for nephrosis in cardio-cerebral vascular disease treated by anticoagulation[J]. Medicine, 2016, 95(38): e4954. doi: 10.1097/MD.0000000000004954
[11]	Liu S, Gong Y, Ren H, et al. The prevalence, subtypes and associated factors of hyperuricemia in lupus nephritis patients at chronic kidney disease stages 1–3[J]. Oncotarget, 2017, 8(34): 57099–57108. doi: 10.18632/oncotarget.19051
[12]	Ameh OI, Kengne AP, Jayne D, et al. Standard of treatment and outcomes of adults with lupus nephritis in Africa: a systematic review[J]. Lupus, 2016, 25(11): 1269–1277. doi: 10.1177/0961203316640915
[13]	Pahar B, Lackner AA, Veazey RS. Intestinal double-positive CD4⁺CD8⁺ T cells are highly activated memory cells with an increased capacity to produce cytokines[J]. Eur J Immunol, 2006, 36(3): 583–592. doi: 10.1002/eji.200535520
[14]	Parel Y, Chizzolini C. CD4⁺ CD8⁺ double positive (DP) T cells in health and disease[J]. Autoimmun Rev, 2004, 3(3): 215–220. doi: 10.1016/j.autrev.2003.09.001
[15]	Dashtsoodol N, Shigeura T, Aihara M, et al. Alternative pathway for the development of V_α14⁺ NKT cells directly from CD4^-CD8^- thymocytes that bypasses the CD4⁺CD8⁺ stage[J]. Nat Immunol, 2017, 18(3): 274–282. doi: 10.1038/ni.3668
[16]	Schäfer S, Zernecke A. CD8⁺ T cells in atherosclerosis[J]. Cells, 2020, 10(1): 37. doi: 10.3390/cells10010037
[17]	Abd El-Kader SM, Al-Shreef FM. Inflammatory cytokines and immune system modulation by aerobic versus resisted exercise training for elderly[J]. Afr Health Sci, 2018, 18(1): 120–131. doi: 10.4314/ahs.v18i1.16
[18]	Wu Z, Zheng Y, Sheng J, et al. CD3⁺CD4^-CD8^- (double-negative) T cells in inflammation, immune disorders and cancer[J]. Front Immunol, 2022, 13: 816005. doi: 10.3389/fimmu.2022.816005
[19]	Glatzová D, Cebecauer M. Dual role of CD4 in peripheral T lymphocytes[J]. Front Immunol, 2019, 10: 618. doi: 10.3389/fimmu.2019.00618
[20]	Pérez-Antón E, Egui A, Thomas MC, et al. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4⁺CD8⁺ T cells in chronic Chagas disease patients[J]. PLoS Negl Trop Dis, 2018, 12(5): e0006480. doi: 10.1371/journal.pntd.0006480
[21]	Wu Y, Cai B, Feng W, et al. Double positive CD4⁺CD8⁺ T cells: key suppressive role in the production of autoantibodies in systemic lupus erythematosus[J]. Indian J Med Res, 2014, 140(4): 513–519. https://pubmed.ncbi.nlm.nih.gov/25488445/
[22]	Frahm MA, Picking RA, Kuruc JD, et al. CD4⁺CD8⁺ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection[J]. J Immunol, 2012, 188(9): 4289–4296. doi: 10.4049/jimmunol.1103701
[23]	Choe JY, Lee SS, Kwak SG, et al. Anti-Sm antibody, damage index, and corticosteroid use are associated with cardiac involvement in systemic lupus erythematosus: data from a prospective registry study[J]. J Korean Med Sci, 2020, 35(21): e139. doi: 10.3346/jkms.2020.35.e139
[24]	Ahn SS, Jung SM, Yoo J, et al. Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus[J]. Rheumatol Int, 2019, 39(11): 1937–1944. doi: 10.1007/s00296-019-04445-y
[25]	Wang X, Xia Y. Anti-double Stranded DNA Antibodies: Origin, Pathogenicity, and Targeted Therapies[J]. Front Immunol, 2019, 10: 1667. doi: 10.3389/fimmu.2019.01667
[26]	Rekvig OP. Anti-dsDNA antibodies as a classification criterion and a diagnostic marker for systemic lupus erythematosus: critical remarks[J]. Clin Exp Immunol, 2015, 179(1): 5–10. doi: 10.1111/cei.12296